Arikace - once a day - well tolerated (Bye- Bye Tobi, very soon!)
Insmed Incorporated (INSM) provided an interim update from the ongoing two-year, open-label extension study - CLEAR-110 - on Arikace. The study is evaluating once-daily Arikace for the treatment of pseudomonas aeruginosa (Pa) in patients suffering from cystic fibrosis (CF).
The data from the study suggested that Arikace was well tolerated. Additionally, sustained improvement from baseline level in Forced Expiratory Volume in One Second (FEV1) and a sustained reduction in density of Pa sputum during treatment was also observed.
How about providing a link, or copy and paste, or some article that proves your statement. They are called facts. Please inform us. It's not that we don't want to take your word, but facts are much better.